{"id":"placebo-canagliflozin","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Genital mycotic infections"},{"rate":"8-12","effect":"Urinary tract infections"},{"rate":"5-10","effect":"Polyuria"},{"rate":"5-8","effect":"Thirst"},{"rate":"0.1-0.2","effect":"Diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL4594217","moleculeType":"Small molecule","molecularWeight":"462.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Canagliflozin blocks SGLT2, a transporter protein in the proximal tubule of the kidney that normally reabsorbs filtered glucose back into the bloodstream. By inhibiting this transporter, the drug allows excess glucose to be excreted in the urine, thereby reducing blood glucose levels in a glucose-dependent manner. This mechanism is independent of insulin secretion or action.","oneSentence":"Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:16.073Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Diabetic kidney disease"},{"name":"Heart failure with reduced ejection fraction"}]},"trialDetails":[{"nctId":"NCT06913647","phase":"PHASE2","title":"Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-02-01","conditions":"ESRD, CKD (Chronic Kidney Disease) Stage 5D","enrollment":30},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT02220920","phase":"PHASE4","title":"Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-08","conditions":"Type 2 Diabetes Mellitus","enrollment":146},{"nctId":"NCT01022112","phase":"PHASE2","title":"An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":383},{"nctId":"NCT01413204","phase":"PHASE3","title":"Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-07","conditions":"Type 2 Diabetes Mellitus","enrollment":272},{"nctId":"NCT03436693","phase":"PHASE3","title":"Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-02-15","conditions":"Diabetic Nephropathy","enrollment":308},{"nctId":"NCT02354235","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":138},{"nctId":"NCT02354222","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":154},{"nctId":"NCT06182839","phase":"PHASE2","title":"Canagliflozin in Advanced Renal Disease With MRI Endpoints","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-05-01","conditions":"ESRD, CKD Stage 4, CKD Stage 5","enrollment":92},{"nctId":"NCT03170518","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-07-21","conditions":"Diabetes Mellitus, Type 2","enrollment":171},{"nctId":"NCT04252287","phase":"PHASE3","title":"A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-03-10","conditions":"Heart Failure","enrollment":476},{"nctId":"NCT02404870","phase":"PHASE1","title":"Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-09-16","conditions":"Healthy Volunteers","enrollment":67},{"nctId":"NCT03298009","phase":"NA","title":"Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)","status":"WITHDRAWN","sponsor":"Université de Sherbrooke","startDate":"2018-05-01","conditions":"Type2 Diabetes, Heart Failure","enrollment":""},{"nctId":"NCT05427084","phase":"PHASE2, PHASE3","title":"Canagliflozin Targeting Vascular Inflammation","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2024-11-15","conditions":"Diabetes Type 2, Coronary Artery Disease","enrollment":24},{"nctId":"NCT02964585","phase":"PHASE4","title":"Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"George Washington University","startDate":"2016-11","conditions":"Type 2 Diabetes Mellitus","enrollment":34},{"nctId":"NCT05422092","phase":"NA","title":"Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-09-20","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT05513729","phase":"","title":"Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-08-18","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT02624908","phase":"PHASE4","title":"Canagliflozin-Mealtime Insulin Rescue","status":"UNKNOWN","sponsor":"Foundation for Atlanta Veterans Education and Research, Inc.","startDate":"2016-01","conditions":"Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT05135039","phase":"NA","title":"Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV.","status":"UNKNOWN","sponsor":"xiaolong zhao","startDate":"2022-01-01","conditions":"PreDiabetes, Hiv","enrollment":218},{"nctId":"NCT02912455","phase":"PHASE4","title":"CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2017-01-05","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":16},{"nctId":"NCT02597049","phase":"PHASE3","title":"A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":424},{"nctId":"NCT03136484","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-03-15","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":788},{"nctId":"NCT02065791","phase":"PHASE3","title":"Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-17","conditions":"Diabetes Mellitus, Type 2, Diabetic Nephropathy","enrollment":4401},{"nctId":"NCT01756404","phase":"PHASE1","title":"Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-06-14","conditions":"Healthy","enrollment":80},{"nctId":"NCT01989754","phase":"PHASE4","title":"A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-16","conditions":"Diabetes Mellitus, Type 2, Albuminuria","enrollment":5813},{"nctId":"NCT01032629","phase":"PHASE3","title":"CANVAS - CANagliflozin cardioVascular Assessment Study","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-12-09","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors","enrollment":4330},{"nctId":"NCT02360774","phase":"PHASE4","title":"Mechanisms of Weight Loss With SGLT2 Inhibition","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2015-02","conditions":"Type 2 Diabetes, Overweight, Obesity","enrollment":30},{"nctId":"NCT02009488","phase":"PHASE1","title":"Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09-08","conditions":"Diabetes Mellitus, Type 2","enrollment":59},{"nctId":"NCT03190798","phase":"PHASE4","title":"Effects of Canagliflozin on Intravascular Volume and Hemodynamics","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-09-01","conditions":"Type2 Diabetes Mellitus, Cardiovascular Diseases","enrollment":""},{"nctId":"NCT01809327","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-06-04","conditions":"Diabetes Mellitus, Type 2","enrollment":1186},{"nctId":"NCT02000700","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":17},{"nctId":"NCT01939496","phase":"PHASE4","title":"Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-10","conditions":"Diabetes Mellitus, Type 2, Hypertension","enrollment":171},{"nctId":"NCT02597309","phase":"PHASE4","title":"The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin","status":"WITHDRAWN","sponsor":"Joslin Diabetes Center","startDate":"2015-11","conditions":"Diabetes, Obesity","enrollment":""},{"nctId":"NCT01081834","phase":"PHASE3","title":"The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-03","conditions":"Diabetes Mellitus, Type 2","enrollment":678},{"nctId":"NCT02025907","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":218},{"nctId":"NCT02243202","phase":"PHASE2","title":"Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09","conditions":"Obesity","enrollment":335},{"nctId":"NCT02139943","phase":"PHASE2","title":"A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-05","conditions":"Diabetes Mellitus, Type 1","enrollment":352},{"nctId":"NCT01787357","phase":"PHASE1","title":"A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-06","conditions":"Healthy","enrollment":60},{"nctId":"NCT02053116","phase":"PHASE2","title":"A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin","status":"TERMINATED","sponsor":"Pfizer","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":8},{"nctId":"NCT01106651","phase":"PHASE3","title":"A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2","enrollment":716},{"nctId":"NCT01340664","phase":"PHASE2","title":"An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-07","conditions":"Diabetes Mellitus, Type 2","enrollment":279},{"nctId":"NCT01483781","phase":"PHASE1","title":"A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-12","conditions":"Diabetes Mellitus, Type 2, Plasma Volume","enrollment":36},{"nctId":"NCT01381900","phase":"PHASE3","title":"A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-08","conditions":"Diabetes Mellitus, Type 2","enrollment":678},{"nctId":"NCT00963768","phase":"PHASE1","title":"A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-06","conditions":"Diabetes Mellitus, Type 2","enrollment":116},{"nctId":"NCT01916863","phase":"PHASE1","title":"Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2013-08","conditions":"Healthy Subjects","enrollment":25},{"nctId":"NCT01064414","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2, Renal Insufficiency","enrollment":272},{"nctId":"NCT01106677","phase":"PHASE3","title":"The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1284},{"nctId":"NCT00642278","phase":"PHASE2","title":"An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-04","conditions":"Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent","enrollment":451},{"nctId":"NCT01106690","phase":"PHASE3","title":"The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT01106625","phase":"PHASE3","title":"The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":469},{"nctId":"NCT01665638","phase":"PHASE1","title":"Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-09","conditions":"Healthy","enrollment":10},{"nctId":"NCT01177163","phase":"PHASE1","title":"A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-05","conditions":"Diabetes Mellitus, Type 2","enrollment":29},{"nctId":"NCT01128985","phase":"PHASE1","title":"A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-03","conditions":"Diabetes Mellitus, Type 2","enrollment":39},{"nctId":"NCT00650806","phase":"PHASE2","title":"A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-05","conditions":"Obesity","enrollment":376},{"nctId":"NCT01381887","phase":"PHASE1","title":"A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-06","conditions":"Diabetes Mellitus, Type 2","enrollment":37},{"nctId":"NCT01707316","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-06","conditions":"Healthy","enrollment":15},{"nctId":"NCT01173549","phase":"PHASE1","title":"A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-11","conditions":"Healthy","enrollment":26},{"nctId":"NCT01177150","phase":"PHASE1","title":"A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-11","conditions":"Healthy","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":428,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (canagliflozin)","genericName":"Placebo (canagliflozin)","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose. Used for Type 2 diabetes mellitus, Diabetic kidney disease, Heart failure with reduced ejection fraction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}